Previous Close | 27.30 |
Open | 29.76 |
Bid | 31.70 |
Ask | 35.60 |
Strike | 185.00 |
Expire Date | 2024-05-17 |
Day's Range | 27.30 - 32.78 |
Contract Range | N/A |
Volume | |
Open Interest | 780 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.